A sermorelin-GHK product combines ingredients with different biological roles and different evidence. GHK is a tripeptide; GHK-Cu is its copper-associated form. A product using one name should not be assumed to contain the other, and neither name establishes that a combined prescription improves skin, strength, or recovery.
The first step is to identify every ingredient and the route. A sublingual tablet, a topical cosmetic, and an injection pose different questions. The sources reviewed for this guide did not establish a controlled human trial validating the clinical benefits of the exact marketed sermorelin-GHK oral combination described below.
A sermorelin-GHK blend needs evidence for its exact ingredients and route. GHK-Cu cell experiments, topical claims, and injected-product warnings cannot be treated as interchangeable findings.
What a current product page establishes
Everlife’s product page describes a compounded prescription formulation containing sermorelin, GHK, and citrulline, marketed as a sublingual mint tablet. That is a source for what the company advertises. It is not independent proof of the promotional outcomes.
The additional citrulline matters: this is not simply a study of sermorelin alone or a two-ingredient mixture. Confirm the current prescription’s full ingredients, amounts, pharmacy, and instructions before comparing it with another service. Our Everlife review separates the company’s different offers and their commercial terms.
We have not ordered or tested this formulation. A public page cannot establish the quality of an individual dispensed lot or confirm that every patient receives the same preparation.
Cell research helps explain a hypothesis
A 2015 laboratory study examined GHK and its copper complex in cultured human dermal fibroblasts, including effects involving growth-factor signaling. Human cells in a laboratory are not the same as people taking a medicine. The experiment did not test a sermorelin-GHK-citrulline tablet.
Such work may explain why researchers investigate a peptide in skin biology. It cannot establish visible wrinkle reduction, wound healing, muscle gain, or improved daily functioning from a different product and route. A cellular response is a starting point for a clinical question, not the answer to it.
Our skin and hair guide explains why cosmetic claims need their own outcomes. Before-and-after images cannot fill the gap left by the absence of a relevant controlled trial.
The oral route adds a separate evidence question
A tablet dissolving under the tongue does not establish how much of each ingredient reaches the bloodstream or relevant tissues. A combination may also have different formulation properties from the single ingredients used in a cited experiment.
Ask whether there are human absorption data for the exact product and whether those data are connected to a meaningful clinical outcome. Our oral bioavailability guide separates dissolution, absorption, hormone response, and benefit. An injection study does not provide an automatic oral equivalence ratio.
A study of a topical copper-peptide product would raise a different translation problem. Applying a preparation to the skin is not the same exposure as taking it orally or injecting it. The evidence should preserve that distinction.
Keep FDA’s route-specific warning in context
The FDA’s peptide safety page discusses potential immune-response risks and limited human safety data for injectable GHK-Cu. This should not be relabeled as a finding about every oral GHK preparation. It also does not establish that an oral product is safe simply because that entry concerns injections.
The FDA compounding overview explains the separate issue of finished-product approval. Ask the prescriber and pharmacist to explain the preparation being offered, rather than treating either the warning or the absence of a named product from a list as a complete assessment.
A larger ingredient list needs a clearer rationale
Ask which symptom or diagnosis each ingredient addresses, what additional benefit is expected from combining them, and how the clinician would assess a new adverse effect. Several ingredients started together can make cause and effect harder to interpret.
If a provider uses the word “synergy,” request the study that tests the combination. Adding conclusions from unrelated ingredient studies does not demonstrate that the finished formula performs better. The stacking guide offers questions for discussing that uncertainty.
Finally, distinguish GHK from glycine-containing preparations. A useful decision rests on the exact prescription and relevant evidence, not the assumption that similarly named blends deliver the same treatment. Obtain a full cost and reassessment plan once those details are clear.
Sources & further reading
Provider pages describe offers; they do not independently establish treatment benefits. Sources checked September 21, 2026.
This article is education, not a diagnosis, prescription, or dosing plan. Discuss treatment and alternatives with a licensed clinician who knows your history. Compounded medications are not FDA-approved.